Beta
Back to ISRG.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • Revenue by Segments
  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
revenue-chart

ISRG Revenue

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

In Q1'26, ISRG's revenue reached $2.77B USD, marking a 22.96% year-over-year growth from the prior year's quarter and continuing the company's strong performance in the latest reported period. From Q2'23 to Q1'26, ISRG's revenue has exhibited a robust upward trend, rising from $1.76B USD to $2.77B USD, with consistent quarter-over-quarter increases averaging around 10-15% and accelerating notably in Q4'24 ($2.41B USD) and Q4'25 ($2.87B USD). Year-over-year growth rates have remained positive throughout, fluctuating between 11% and 25%, with peaks in Q3'24 (16.88%) and Q1'26 (22.96%), underscoring sustained demand and operational expansion in the medical technology sector. No significant declines or volatility were observed, reflecting stable and accelerating growth momentum over the 3-year quarterly timeframe.